KMT2A and leukemia: In addition, inducible HIF1α deletion in the MLL-AF9 model resulted in increased recovery upon withdrawal of chemotherapeutic regimens (112), thus suggesting that HIF1α inhibition cannot be expected to improve chemotherapy sensitivity in all leukemia.